ABSTRACT
Methods: To compare radiologic with different pathologic assessments of invasive tumor size, we retrospectively reviewed a cohort of resected nmLACAs with a partsolid appearance on computed tomography (CT) scan (n = 112).

Results: The median direct microscopic pathologic invasive measurements were not significantly different from the median calculated pathologic invasive measurements; however, the median CT invasive measurements were 0.26 cm larger than the median direct pathologic measurements (P < .001).
Conclusions: Our results show that pathologic calculated invasive tumor measurements are comparable to direct microscopic measurements of invasive tumor, thereby supporting the recommendation for use of calculated invasive tumor size by the pathologist if necessary.
The new eighth edition of the American Joint Committee on Cancer (AJCC) cancer staging manual has changed the way in which nonmucinous lung adenocarcinomas (nmLACAs) are staged. 1 The update now requires that T descriptors for these lung adenocarcinomas are no longer based on overall tumor size but rather on the size of the invasive (ie, nonlepidic) component only. 2 This change was proposed by the International Association for the Study of Lung Cancer based on the concept of lepidic growth as in situ proliferation and nonlepidic growth as invasive carcinoma, 3 moving it in line with other forms of cancer that have well-defined in situ growth components. This change is supported by recent data that suggest that invasive size is superior to overall tumor size for predicting survival outcomes. [4] [5] [6] [7] [8] [9] [10] [11] [12] Although much of these data were based on computed tomography (CT) measurements without pathologic correlation, recent studies have highlighted the prognostic significance of the invasive component [13] [14] [15] and show that CT-assessed solid components correlate well with invasive histologic patterns. 16, 17 The pathologic measurement of the invasive component can be particularly challenging. Invasive and noninvasive components cannot reliably be differentiated at the time of gross specimen evaluation, 3 and multiple factors can lead to inaccurate measurements, such as tumor shrinkage due to formalin fixation, surrounding nonneoplastic components erroneously included in the gross tumor size, and measurement biases. 18 As such, microscopic confirmation of the invasive size is generally required. For larger tumors that cannot fit on a single slide, the true size of the invasive component cannot be accurately measured directly. For cases such as these, the eighth edition of the AJCC manual recommends estimation of the invasive component by multiplying the percentage of invasive components (ie, any nonlepidic growth pattern: solid, acinar, papillary, micropapillary) by the overall size of the tumor. 2 This necessitates adequate tumor sampling so that the architectural patterns can be accurately categorized. In our review of the literature, to date, no studies have validated the recommendation that use of calculated invasive tumor size correlates with a direct invasive tumor size measurement. As such, we aimed to assess how pathologic invasive tumor size calculation compares with direct microscopic measurement of the invasive component (the current gold standard) by retrospectively examining nmLACAs resected at our institution between 2005 and 2016 that were defined as "part-solid" (ie, containing both a ground-glass and a solid/soft tissue component) by presurgical CT scans. We also evaluated how closely the radiologic assessment of invasive tumor size compared with the ultimate pathologic invasive tumor size measurements.
Materials and Methods
Study Material
Following approval by our institutional review board (protocol 15-020), the electronic medical record system and pathology department laboratory information system were searched for all lung adenocarcinoma specimens (wedge, segmentectomy, or lobectomy) surgically resected at our institution between January 2005 and July 2016 to establish a repository of CT pathologic data. A total of 534 surgically resected lung adenocarcinomas were identified that had preresection CT scans available, which established the working database. From this database, only those that were defined as "part-solid" by CT were included in this study. These were cases that contained both a ground-glass opacity component (eg, inferred in situ component) and a solid/soft tissue component (eg, inferred invasive component). From the database, 121 (22.7%) of 534 were considered part-solid by radiologist review (B.H.H. and A.A.B.). Of these 121 available partsolid resected lung adenocarcinoma (LACA) cases, only those that were histologically nmLACAs and where the invasive component fit on either a single glass slide or on paired slides (eg, cross-sectional slice through tumor cut in half and placed into two consecutive tissue cassettes) were included in this study, which resulted in a final case number of 112. Additional studies have been conducted on other subsets of the database, including radiologic-pathologic correlations of adenocarcinomas manifesting as solid lung nodules and as pure ground-glass nodules, but no studies specifically have looked at part-solid lung nodules. [18] [19] [20] [21] [22] 
CT Acquisition
CT scans were acquired over our entire hospital network using various CT scanner units and acquisition protocols. All CT scanner units were considered state of the art at the time of acquisition. The most frequent CT units were Aquilion One (320-detector row; Toshiba, Tustin, CA), Discovery CT750 HD (64-detector row; GE Medical Systems, Waukesha, WI), and Lightspeed VCT (GE Medical Systems, 64-detector row).
All CT examinations were performed over the entire thorax, in supine body position at full suspended inspiration. Until April 2007, examinations were performed with fixed mAs (range, 130-340 mAs) and 120 kVp. After April 2007, they were performed using automated exposure control and other dose reduction algorithms. Only images reconstructed in the transverse plane in lung window settings (mean, −500 HU; width, 1,500 HU) were used in this study.
Pathologic Tumor Assessment
The surgically resected tumors were formalin fixed and grossly evaluated and processed by anatomic pathology residents according to the departmental standard operating procedures. The gross pathologic measurements of the lung tumors were performed at the time of grossing. Measurements were recorded in three dimensions, rounded to the nearest millimeter, after formalin inflation, fixation, and serial sectioning of the resection specimen. The greatest measured dimension was used for the pathologic T descriptor at the time of case signout, corresponding to the "overall tumor size" measure. All measurements were included in the pathology report gross description as well as in the synoptic reporting portion of the final pathology report.
Slides from all of the cases were re-reviewed by two pathology residents (K.R.A. and A.O.), followed by final review by a thoracic pathology subspecialty-trained surgical pathologist (P.A.V.L.), with discussion and subsequent review of any discrepant findings. For each tumor, the histologic growth patterns (lepidic, acinar, papillary, micropapillary, and solid) were tabulated in 5% increments. Overall tumor size for small tumors that completely fit on a single or paired glass slides was confirmed by direct microscopic measurement. In cases where this was not possible, the overall gross tumor size was used. Direct measurement of the invasive tumor size was performed by marking the boundaries of the invasive (ie, nonlepidic) architectural patterns on the glass slide and measuring the longest axis with a ruler. The calculated invasive tumor size was obtained by multiplying the overall tumor size measurement by the percentage of invasive patterns (eg, calculated invasive size = [overall tumor size in centimeters] × [% acinar + % solid + % papillary + % micropapillary]).
Radiologic Tumor Assessment
CT data were acquired over our entire hospital network using various protocols, which were detailed in prior publications. [18] [19] [20] [21] [22] CT diameters of the largest solid nodule component of all LACAs were measured by one radiology observer (B.H.H.), using a click-and-drag digital line-caliper tool built into the picture archiving and communication system. All measurements were performed in lung window settings on the transverse CT section showing the greatest tumor dimension per standard protocols. The measured long-axis CT diameter was displayed to the tenth of a millimeter but was recorded and rounded to the nearest millimeter for clinical/CT tumor size assessment in this study.
Statistical Analysis
Direct microscopic pathologic invasive measurements, calculated pathologic invasive measurements, and CT measurements of the solid component were examined for normality of distribution using histograms and the Shapiro-Wilk test. The samples did not follow a normal distribution, so nonparametric Wilcoxon signed-rank tests for repeated samples were performed to compare the differences between measurement methods. T descriptor assignment according to the eighth edition of the AJCC cancer staging manual of different measurements was analyzed for homogeneity using the Bhapkar test. Data analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC), with the level of statistical significance set at P < .05.
Results
The overall patient and tumor demographics for the cases used in this study are displayed in ❚Table 1❚. The median and mean gross pathologic tumor sizes were 1.50 and 1.66 cm, respectively. When directly measured, the median size of the invasive component was 0. (Table 2) ; both differences were statistically significant (P < .001).
The breakdown of corresponding T descriptors according to the invasive component of each case can be seen in ❚Figure 1❚. In our cohort, direct pathologic invasive size measurements gave two, 47, 25, 34, and four cases that were classified as adenocarcinoma in situ pTis(AIS), minimally invasive adenocarcinoma pT1mi, pT1a, pT1b, and pT1c, respectively. Based on pathologic calculated invasive Table 3) . The difference in percentages of downstaged, unchanged, and upstaged measured on CT and by pathologic calculated method compared with direct pathologic measurements is statistically significant (P < .001).
Discussion
In this study, we selected a focused cohort of resected nmLACAs that contained both an in situ and invasive tumor component to assess how well direct pathologic measurement of invasive tumor size (gold standard) correlates with either a calculated pathologic invasive component size or the preresection CT soft tissue component size. Our results showed no significant difference (median, 0.02 cm; mean, 0.0004 cm; effect size r = 0.028) in the pathologic size of the invasive component when measured directly vs by calculated estimation. We performed a post hoc power analysis, which indicated that our study with a total sample size of 112 had adequate statistical power (83%) to detect a medium difference (effect size r = 0.3). 23, 24 In other words, if pathologic direct measurements had had a "medium" size difference from the calculated estimations, we would have found a statistically ❚Figure 1❚ Sankey diagram comparing T stages of cases when measured by direct measurement, invasive component estimation, and computed tomography soft tissue component. AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma.
significant difference. Therefore, this study gives convincing negative results. However, we found that CT measurements of the invasive component were significantly larger than measurements by the two pathologic methods. In addition, with direct pathologic invasive measurements used as a baseline, a significantly greater number of cases would have been T descriptor upstaged when assessed by CT than when classified by pathologic invasive component calculation. This suggests that pathologic calculated estimation of the invasive component is an accurate and reliable representation of the true invasive size. A representative case can be seen in ❚Image 1❚. The gross appearance (Image 1A) correlates well with what was seen on representative histology (Image 2C). While the CT image (Image 2B) clearly shows a soft tissue component surrounded by a ground-glass component, it does not show a similar cross-section appearance, highlighting the difficulty in directly comparing pathologic with CT measurements. The boxed area in Image 1A highlights a gross area suspicious for an in situ component. When this area is examined histologically (Image 1D), a gradient between the lepidic component (upper right) and the adjacent acinar invasive pattern (lower left) can be seen. This highlights the potential difficulty the pathologist can face in determining precise cutoff boundaries for lepidic/in situ vs invasive components at the microscopic level as well.
An issue with estimation of the invasive component is the difficulty in reproducibly determining the histologic growth pattern breakdown of a tumor. While studies have shown decent interobserver agreement on the predominant pattern of a given tumor, discerning between invasive and in situ components can be difficult. 25, 26 Although sufficient training can improve this agreement, 27 the delineation between invasive and lepidic in situ morphology can still be challenging, especially in areas of transition from an invasive to lepidic growth pattern. 28 These transitions can show a gradient of cytologic and morphologic changes that can preclude accurate characterization. In addition, it has been shown that there is greater interobserver variability in cases with larger numbers of glass slides to evaluate. 25 This may have implications in extrapolating the results of this study to much larger tumors with either multiple foci of invasion or where the invasion cannot be easily captured on a single slide or contiguous slides. In such instances, the recommendation to rely on the overall percentage breakdown of architectural growth patterns seems reasonable and perhaps more readily assessed in establishing a calculated invasive tumor size used for pathologic T descriptor staging.
Our data show that on average, measurements by CT result in larger invasive tumor sizes than both pathologic direct invasive measurements and pathologic invasive size calculated estimations and thus result in significantly more frequent upstaging of tumors than pathologic invasive component estimation with respect to pathologic direct measurements. This is not surprising, since previous studies have also shown that CT measurements yield larger tumor measurements than pathology. 29 This is a multifactorial phenomenon, likely attributed to issues with tumor shrinkage with fixation 30 ; lung and, to a lesser extent, tumor collapse when removed from the negative pressure of the chest cavity; and grossing techniques leading to measurement differences. In addition, it may be difficult if not impossible for the radiologist to discern tumor from associated nonneoplastic lung changes, including scarring, fibrosis, or peritumoral inflammation that all could mimic the invasive component of a lung nodule with the solid appearance on a CT scan. Last, it should be noted that pathologic measurements in this study were obtained without strict adherence to prespecified anatomic plane of sectioning (ie, the greatest dimension recordable on any axis). However, CT measurements are by convention generally obtained on the transverse plane, 31 and as such, the largest radiologic measured dimension might not routinely take into account if the coronal or sagittal planes show a larger tumor size. This may account for some of the differences seen in the measured sizes. Regardless, our study confirms these previous observations in the difference between pathologic and CT measurements and extends them to assessment of the invasive component measurements as well.
This study has some limitations that warrant discussion. Clinical outcome data were not available for our data set, and as such, the clinical impact of discordant radiologic and pathologic measurements could not be ascertained. This study was also not designed to assess intraobserver variability either on the part of the radiologist or the pathologist in assessing invasive tumor size. While an important issue that warrants further investigation in subsequent studies, our goal was to minimize observer-to-observer variability by relying on a single radiologist and a single pathologist to provide measurements, respectively. In doing so, we more closely reflect the real-world clinical assessment of tumors, with the CT scan read by a single radiologist and the final pathology report issued by a single pathologist. Last, since this study only analyzed nodules that had invasive components that would fit entirely on one slide or two connecting slides (so that an accurate microscopic direct invasive tumor size measurement could be obtained for all cases), data regarding larger resected lung cancers were not obtained. Pathologic evaluation of larger masses in general are more difficult than smaller tumors, given the need to evaluate multiple tumor sections to appreciate the tumor heterogeneity that could be completely assessed on one or two slides for a smaller tumor. As a true gold-standard direct microscopic measurement of the entire mass or the contiguous invasive component cannot be obtained in larger tumors, one can only extrapolate the findings we report here for smaller tumors and assume they hold true for larger resected nmLACAs as well.
In summary, our study shows that pathologic estimation of the invasive component of nmLACAs with a part-solid appearance on CT correlates well with the current gold standard of direct pathologic microscopic measurement for determination of lung cancer staging T descriptors in the current eighth edition AJCC practice. This implies that when invasive size cannot be assessed by direct pathologic measurement, calculated invasive size based on percentages of invasive growth multiplied by the total tumor size is a viable alternative to accurately stage patients with lung cancer. This is especially important in cases where the tumor cannot fit in a single block or where other factors, such as margin assessment, may preclude the assessment of a full cross section of tumor.
